Surgical Science Sweden AB
STO:SUS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
113.7
193.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Surgical Science Sweden AB
Total Equity
Surgical Science Sweden AB
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Surgical Science Sweden AB
STO:SUS
|
Total Equity
kr4.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Elekta AB (publ)
STO:EKTA B
|
Total Equity
kr10.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Total Equity
kr767.9m
|
CAGR 3-Years
15%
|
CAGR 5-Years
19%
|
CAGR 10-Years
19%
|
|
|
Getinge AB
STO:GETI B
|
Total Equity
kr30.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Total Equity
kr7.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Total Equity
kr672.6m
|
CAGR 3-Years
70%
|
CAGR 5-Years
47%
|
CAGR 10-Years
34%
|
|
Surgical Science Sweden AB
Glance View
Surgical Science Sweden AB engages in the development of simulators for laparoscopic medical training. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-06-19. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.
See Also
What is Surgical Science Sweden AB's Total Equity?
Total Equity
4.4B
SEK
Based on the financial report for Sep 30, 2024, Surgical Science Sweden AB's Total Equity amounts to 4.4B SEK.
What is Surgical Science Sweden AB's Total Equity growth rate?
Total Equity CAGR 5Y
63%
Over the last year, the Total Equity growth was -2%. The average annual Total Equity growth rates for Surgical Science Sweden AB have been 9% over the past three years , 63% over the past five years .
You don't have any saved screeners yet
